BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
OCREVUS ZUNOVO (ocrelizumab and hyaluronidase) by Roche is cd20-directed antibody interactions [moa]. Approved for endoglycosidase [epc]. First approved in 2024.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCREVUS ZUNOVO is a CD20-directed monoclonal antibody combined with hyaluronidase for subcutaneous injection, approved September 2024. It works by targeting CD20-positive B cells to modulate immune response. The hyaluronidase component enables rapid subcutaneous delivery, improving patient convenience over intravenous administration.
Growth
Recent approval positions this as a growth-stage asset with expanding market opportunity; commercial teams are in early-stage demand generation and market development phase.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
Started Nov 2018
51 enrolled
Multiple SclerosisRelapsePrimary Progressive Multiple Sclerosis
Career Relevance
OCREVUS ZUNOVO offers career opportunity in a newly approved, growth-stage biologic from a large pharmaceutical sponsor with deep infrastructure. Roles span commercial launch strategy, patient access solutions, medical education, and ongoing regulatory management of a novel delivery innovation.
Brand Manager
Worked on OCREVUS ZUNOVO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.